Thursday 16 October, 2025
Objectives: Enoxaparin is a low molecular weight heparin (LMWH) used in the treatment of thrombosis. Unlike unfractionated heparin (UFH), no…
Read morePoster: Applications- Coagulation
A longitudinal model describing the relationship between warfarin dose and INR response taking CYP2C9, VKORC1 and age into account
Thursday 16 October, 2025
Objectives: To reformulate and update a previous NONMEM model [1] for the relationship between warfarin dose and INR response. Methods: The…
Read moreInternal and external evaluation of a K-PD model for warfarin using prediction corrected visual predictive check (PC-VPC)
Thursday 16 October, 2025
Objectives: To evaluate the performance of a warfarin K-PD model using PC-VPCs in both an internal [1] and [2] external…
Read moreA comprehensive model for the coagulation network in humans
Thursday 16 October, 2025
Introduction: Coagulation is an important process in haemostasis. Experimental tests of clotting are difficult to conduct and interpret, because (a)…
Read moreAssessment of pharmacokinetic variability of fondaparinux in 809 patients treated after major orthopedic surgery: the POP-A-RIX study
Thursday 16 October, 2025
Objectives: Fondaparinux is a synthetic antithrombotic agent with specific anti–factor Xa activity. Despite a favorable benefit risk ratio in average,…
Read moreThe use of an indirect response model to assess interaction between drugs: acenocoumarol and amoxicillin + clavulanic acid
Thursday 16 October, 2025
Objectives: It has been reported in the literature an increase of anticoagulation level, assessed by prothrombin time, when acenocoumarol, an…
Read moreNon-Linear Population Pharmacokinetic Model for Otamixaban in Healthy Male Subjects
Thursday 16 October, 2025
PDF of poster Objectives: Otamixaban is a direct Factor Xa inhibitor for the intravenous treatment of arterial thrombosis. Healthy subjects…
Read morePharmacokinetic variability of the absorption of enoxaparin used subcutaneously for venous thromboembolism prophylaxis
Thursday 16 October, 2025
PDF of poster Introduction: The use of enoxaparin for the prophylaxis of venous thromboembolism (VTE) after orthopaedic surgery leads to…
Read morePopulation PK/PD Modeling of Eltrombopag in ITP Patients and Optimization of Response-Guided Dosing
Thursday 16 October, 2025
Background: Eltrombopag is the first oral, small molecule, non-peptide thrombopoietin receptor (TPO-R) agonist. It has been shown to induce differentiation…
Read morePopulation Pharmacokinetics of Eltrombopag in Healthy Subjects and Patients with Chronic Idiopathic Thrombocytopenic Purpura
Thursday 16 October, 2025
Objectives: Eltrombopag is an orally bioavailable small molecule agonist of thrombopoietin receptor (TPO-R) that has been recently approved for treatment…
Read more